Draft:TissueLabs

This may take 2 months or more, since drafts are reviewed in no specific order. There are 2,344 pending submissions waiting for review.

Draft:TissueLabs
  • Comment: It is still very much in promotional language rather than that of an encyclopedia. For example "used by research laboratories worldwide" is not what an encyclopedia will say. The aspiration of an artificial cardiac device is what a company promotion would say, not an encyclopedia.
    If you have a conflict of interest under WP:COI then for important transparency reasons this needs to be declared fully. ChrysGalley (talk) 10:38, 19 February 2026 (UTC)


TissueLabs SA
TypePrivate
IndustryBioengineering
Founded02/01/2019
Founder
Key people
  • Gabriel Liguori (CEO)
  • Emerson Moretto (CTO)
  • Felipe Brito (CFO)
  • Tácia Liguori (CSO)
Products3D Bioprinters and Biomaterials
Number of employees
~10
Websitehttps://www.tissuelabs.com/

TissueLabs is a Swiss biotechnology company focused on tissue engineering and biofabrication. Headquartered in Bellinzona, Ticino, Switzerland, the company develops 3D bioprinters and tissue-specific biomaterials for use in laboratory research applications including drug testing, disease modeling, and cell culture.[1][2][3]

History

Founding

TissueLabs was founded in January 2019 in Brazil by Gabriel Liguori and Emerson Moretto. The company originated in the IPEN-Cietec incubator at the University of São Paulo and raised approximately $1.6 million in seed funding during its initial phase of development.[1] Liguori, a medical doctor and researcher with a doctorate in cardiovascular regenerative medicine from the University of Groningen, had previously been named to the Forbes 30 Under 30 list in 2018[4] and to the MIT Technology Review Innovators Under 35 list in 2020.[5]In 2021, TissueLabs relocated its headquarters to Switzerland, initially based in Manno before moving to Bellinzona.

Early development

During its early development, TissueLabs focused on laboratory tools for tissue engineering research. In 2019, the company introduced MatriXpec, a line of tissue-specific hydrogels derived from decellularized extracellular matrix, developed for use in three-dimensional cell culture and bioprinting. By 2020, formulations had been developed for tissue types including myocardium, lung, liver, kidney, skin, and cartilage.[6][7][8]

Also in 2020, TissueLabs introduced TissueStart, an extrusion-based 3D bioprinter designed for academic and laboratory use.[1]

In early 2020, during the COVID-19 pandemic, TissueLabs developed MatriWell, an in vitro system combining a cell culture insert with lung-derived hydrogels to model aspects of lung epithelium. The system was made available at no cost for research use in studies of SARS-CoV-2 infection in pulmonary cells.[9] MatriWell was subsequently used in a 2023 peer-reviewed research examining three-dimensional models for respiratory disease investigation.[10]

Growth

In 2021, TissueLabs introduced TissueRay, an MSLA-based 3D bioprinter. The system was presented at the annual congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS).[2]

In 2023, TissueLabs closed a pre-seed financing round of $800,000, led by Mergus Ventures, with participation from MIT Angels and others. The funds supported the establishment of a new biofabrication facility in Bellinzona, which began operations in early 2024.[11][12]Initially based in Manno, the relocation to Bellinzona was related to being closer to European biotech and research networks.[1] In 2024, TissueLabs was selected to participate in the Venture Leaders Biotech program, a Swiss initiative supporting early-stage biotechnology companies. In 2025, TissueLabs introduced TissuePro, a 3D bioprinter with five independent extrusion heads designed for more complex tissue engineering applications.[13][14][3] In that year, the company was also included in the Top 100 Startups to Watch list published by Pequenas Empresas & Grandes Negócios (PEGN) that year.[15]

Research direction

According to statements by the company and its founder, TissueLabs is pursuing long-term research into the development of a bioartificial heart[16] using patient-derived cells. In a 2021 interview, Liguori stated that clinical trials for such a device could require an additional 10–15 years of research and development.[4][3][17]

References

  1. ^ a b c d Listek, Vanesa (2021-10-16). "Bioprinting Startup TissueLabs Moves HQ from Brazil to Switzerland". 3DPrint.com. Retrieved 2026-04-01.
  2. ^ a b Listek, Vanesa (2021-12-02). "New Masked SLA Bioprinter Revealed by TissueLabs". 3DPrint.com. Retrieved 2026-04-01.
  3. ^ a b c Abirascid, Emil (2026-04-27). "From patient to pioneer: the entrepreneur revolutionising organ transplants". Startupbusiness.it. Retrieved 2026-05-15.
  4. ^ a b Riga, Matheus (2021-07-01). "Healthtech brasileira está no caminho para viabilizar impressão em 3D de órgãos humanos". Forbes Brasil (in Brazilian Portuguese). Retrieved 2026-04-01.
  5. ^ "Gabriel Liguori". MIT Technology Review Innovators Under 35. Retrieved 2026-04-01.
  6. ^ "Estas empresas vão mudar a forma como cuidamos da nossa saúde". Época Negócios (in Brazilian Portuguese). 2022-08-24. Retrieved 2026-04-01.
  7. ^ Josino, Raphaella; Stimamiglio, Marco Augusto (2023). "Bioactive decellularized extracellular matrix-based hydrogel supports human adipose tissue-derived stem cell maintenance and fibrocartilage phenotype". Frontiers in Bioengineering and Biotechnology. 11 1304030. doi:10.3389/fbioe.2023.1304030. ISSN 2296-4185. PMC 10800544. PMID 38260748.
  8. ^ Dos Santos, Jeniffer Farias; Freitas-Marchi, Bruna Letícia; Reigado, Gustavo Roncoli; de Assis, Silvia Romano; Maria Engler, Silvya Stuchi; Chambergo Alcalde, Felipe Santiago; Nunes, Viviane Abreu (2022). "Mesenchymal stem cells express epidermal markers in an in vitro reconstructed human skin model". Frontiers in Cell and Developmental Biology. 10 1012637. doi:10.3389/fcell.2022.1012637. ISSN 2296-634X. PMC 9878690. PMID 36712971.
  9. ^ "TissueLabs: New 3D Printed Platform Free to Researchers Studying COVID-19". 3DPrint.com. 2020. Retrieved 2026-04-01.
  10. ^ Seixas, Maria Luiza; Bartolomeo, Cynthia Silva; Lemes, Robertha; Nicoliche, Tiago; Okuda, Liria Hiromi; Martins, Leonardo; Ureshino, Rodrigo; Prado, Carla Maximo; Liguori, Tácia Tavares Aquinas; Liguori, Gabriel Romero; Stilhano, Roberta Sessa (2023-09-01). "Disruptive 3D in vitro models for respiratory disease investigation: A state-of-the-art approach focused on SARS-CoV-2 infection". Biomaterials and Biosystems. 11 100082. doi:10.1016/j.bbiosy.2023.100082. ISSN 2666-5344. PMC 10391659. PMID 37534107.
  11. ^ "TissueLabs begins biofabrication activities in Bellinzona". Greater Zurich Area. 2024-03-25. Retrieved 2026-04-01.
  12. ^ "TissueLabs secures $800 k and unveils new biofabrication hub in Bellinzona". www.startupticker.ch. Archived from the original on 2025-08-09. Retrieved 2026-06-05.
  13. ^ Duran, Paloma (2025-06-12). "TissueLabs Scales Bioprinting with Launch of TissuePro: Technical Specifications". 3D Printing Industry. Retrieved 2026-04-01.
  14. ^ "TissueLabs launches new TissuePro extrusion-based bioprinter". VoxelMatters. 2025-06-02. Retrieved 2026-04-01.
  15. ^ "Conheça as 100 Startups to Watch 2025". Pequenas Empresas & Grandes Negócios. 2025. Retrieved 2026-04-01.
  16. ^ Liguori, Gabriel R. (2025). "The Bioartificial Heart: Our Mission to Mars". Brazilian Journal of Cardiovascular Surgery. 40 (1): e20250044. doi:10.21470/1678-9741-2025-0044. PMC 11927143. PMID 40105295.
  17. ^ "Rate limit reached". scholar.archive.org. Retrieved 2026-06-05.


Category:Biotechnology companies of Switzerland Category:Companies based in Ticino Category:Tissue engineering Category:3D printing companies Category:Companies established in 2019

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.